Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation
Open Access
- 27 October 2014
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 50 (2) , 237-243
Abstract
Allo-SCT using unrelated donors is a curative treatment for patients with hematological disorders. The best donor is one matched for 10/10 HLA alleles, however studies have shown an additional survival benefit when considering other genetic factors. It has been shown that a six-nucleotide insertion/deletion polymorphism in the CASP8 gene promoter results in reduced susceptibility of T lymphocytes to undergo apoptosis. In 186 SCT recipients, we found a significantly better OS in those who received a transplant from a WT/WT donor compared with donors with a deletion (3 years: 52 vs 34%; P=0.03; multivariate analysis; RR 0.61; 95% CI 0.38–0.98, P=0.04). This was more marked when both the patient and the donor had a deletion (3 years OS: 62% compared with 36%, P=0.01). As the majority of these patients received Alemtuzumab during conditioning, we went on to analyze the in vitro effect of the polymorphism on Alemtuzumab-induced apoptosis. We showed statistically significantly higher percentages of apoptotic naïve CD4 (PPCASP8 promoter polymorphism on survival following unrelated SCT particularly in the context of T-cell depletion with Alemtuzumab.Keywords
This publication has 26 references indexed in Scilit:
- Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated CytolysisPLOS ONE, 2012
- CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expressionLeukemia, 2011
- Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemiaBlood, 2010
- Genetic variation in caspase genes and risk of non-Hodgkin lymphoma: a pooled analysis of 3 population-based case-control studiesBlood, 2009
- High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantationBlood, 2007
- Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphomaCarcinogenesis, 2006
- Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanismLeukemia, 2005
- Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cellsLeukemia & Lymphoma, 2005
- Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantationBlood, 2003
- Fas(CD95)/FasL interactions required for programmed cell death after T-cell activationNature, 1995